Intranasal Dexmedetomidine Versus Intravenous Dexmedetomidine for Improving Quality of Endoscopic Sinus Surgery

• Status: Recruiting
• Trial end date: 2023-12-15
• Target enrollment: 0
• Participant gender: All

Summary

compare intranasal dexmedetomidine versus intravenous dexmedetomidine for improving quality of the operative field in Functional endoscopic sinus surgery

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kafrelsheikh University
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

• Patients underwent Functional Endoscopic Sinus Surgery

• American Society of Anesthesiologists (ASA) physical status classification I or II

Exclusion Criteria:

• Patients with a body mass index > 30 kg/m2 existing or recent significant disease

• contraindications to the use of dexmedetomidine

• history or presence of a significant disease significant cardiovascular disease risk factors

• significant coronary artery disease or any known genetic predisposition

• history of any kind of drug allergy

• drug abuse

• psychological or other emotional problems

• special diet or lifestyle

• clinically significant abnormal findings in physical examination, electrocardiographic (ECG) or laboratory screening

• known systemic disease requiring the use of anticoagulants, patients with a history of previous Functional Endoscopic Sinus Surgery